$Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study$

Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study

Summary Background Chemotherapy has historically proven ineffective in advanced differentiated thyroid cancers, but the realisation that various tyrosine kinases are activated in the disease suggested a potential therapeutic role for tyrosine-kinase inhibitors. We investigated the safety and efficac...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The lancet oncology 2010-10, Vol.11 (10), p.962-972
Hauptverfasser:	Bible, Keith C, Dr, Suman, Vera J, Prof, Molina, Julian R, MD, Smallridge, Robert C, Prof, Maples, William J, MD, Menefee, Michael E, MD, Rubin, Joseph, Prof, Sideras, Kostandinos, MD, Morris, John C, MD, McIver, Bryan, MB, Burton, Jill K, Webster, Kevin P, Bieber, Carolyn, Traynor, Anne M, MD, Flynn, Patrick J, MD, Goh, Boon Cher, MBBS, Tang, Hui, PhD, Ivy, Susan Percy, MD, Erlichman, Charles, Prof
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Cell Differentiation Disease Progression Disease-Free Survival Female Hematology, Oncology and Palliative Medicine Humans Indazoles Iodine Radioisotopes - therapeutic use Male Middle Aged Protein Kinase Inhibitors - adverse effects Protein Kinase Inhibitors - therapeutic use Pyrimidines - adverse effects Pyrimidines - therapeutic use Radiography Radiopharmaceuticals - therapeutic use Sulfonamides - adverse effects Sulfonamides - therapeutic use Thyroid Neoplasms - diagnostic imaging Thyroid Neoplasms - drug therapy Thyroid Neoplasms - mortality Thyroid Neoplasms - radiotherapy Thyroid Neoplasms - secondary Time Factors Treatment Failure United States Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!